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Abstract 
Background: The coronavirus disease 2019 (COVID-19) pandemic remains ongoing around the world, including in 
areas where dengue is endemic. Dengue and COVID-19, to some extent, have similar clinical and laboratory features, 
which can lead to misdiagnosis, delayed treatment and patient’s isolation. The use of rapid diagnostic tests (RDT) is 
easy and convenient for fast diagnosis, however there may be issues with cross-reactivity with antibodies for other 
pathogens.
Methods: We assessed the possibility of cross-reactivity between SARS-CoV-2 and dengue antibodies by: (1) testing 
five brands of COVID-19 IgG / IgM RDTs on 60 RT-PCR-confirmed dengue samples; (2) testing 95 RT-PCR-confirmed 
COVID-19 samples on dengue RDT; and (3) testing samples positive for COVID-19 IgG and/or IgM on dengue RDT.
Results: We observed a high specificity across all five brands of COVID-19 RDTs, ranging from 98.3 to 100%. Out of 
the confirmed COVID-19 samples, one patient tested positive for dengue IgM only, another tested positive for dengue 
IgG only. One patient tested positive for dengue IgG, IgM, and NS1, suggesting a co-infection. In COVID-19 IgG and/
or IgM samples, 6.3% of COVID-19 IgG-positive samples also tested positive for dengue IgG, while 21.1% of COVID-19 
IgM-positive samples also tested positive for dengue IgG.
Conclusion: Despite the high specificity of the COVID-19 RDT, we observed cross-reactions and false-positive results 
between dengue and COVID-19. Dengue and COVID-19 co-infection was also found. Health practitioners in dengue 
endemic areas should be careful when using antibody RDT for the diagnosis of dengue during the COVID-19 pan-
demic to avoid misdiagnosis.
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Background
Severe acute respiratory coronavirus 2 (SARS-CoV-2) 
emerged in Wuhan, China, causing a respiratory dis-
ease, coronavirus disease 2019 (COVID-19), and has 
now resulted in a global pandemic [1]. The pandemic 
remains ongoing in many countries, including areas 
where dengue is endemic, such as Indonesia, which adds 
a burden to health systems [2, 3]. There were over 130 
000 reported cases of dengue in Indonesia in 2019 with 
an incidence rate of 51.48 cases per 100 000 population, 
an increase from the previous year’s incidence of 24.75 
cases per 100 000 population. As of 21 June, there are 68 
000 cases of dengue reported across Indonesia in 2020, 
while COVID-19 cases continue to increase [4]. As of 26 
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Jan 2021, there are over one million confirmed cases of 
COVID-19 in Indonesia [5]. Dengue fever and COVID-
19 have similar clinical and laboratory features, which 
can lead to misdiagnosis, delayed treatment, and isola-
tion [3]. In both cases, patients often report acute fever, 
myalgia, fatigue, and other flu-like symptoms, as well as 
present with thrombocytopenia and leukopenia [1, 3]. 
Most commercial rapid diagnostic tests (RDT) avail-
able in the market are for the detection of SARS-CoV-2 
antibodies, with relatively high sensitivity and specific-
ity, especially when samples are taken later in the disease 
progression [6]. However, it is hampered by the apparent 
cross-reactivity resulting in false-positive results [7]. For 
dengue, immunochromatographic tests for the detection 
of dengue virus nonstructural protein 1 (NS1) antigen, 
IgM, IgG, and IgA antibodies have been developed by a 
number of commercial companies and have found wide 
application because of their ease of use and rapidity of 
results [8, 9].
Methods
In this study, we assessed the possibility of dengue and 
SARS-CoV-2 antibody cross-reactivity using three 
strategies. Firstly, we evaluate the specificity of five 
COVID-19 RDT brands against 60 well-characterized 
RT-PCR-confirmed dengue patient’s serum panel. Sec-
ondly, we test 95 RT-PCR-confirmed clinical COVID-
19 samples on dengue RDT. And thirdly, we test 49 sera 
from healthy, asymptomatic individuals that are positives 
for COVID-19 IgG and/or IgM antibodies on dengue 
RDT (Table 1). The use of archived dengue patients’ sam-
ples has been approved by Eijkman Institute Research 
Ethics Committee, approval number 151/2020, while 
the use of COVID-19 RT-PCR confirmed samples has 
been approved by Bali Mandara District Hospital Health 
Research Ethics Committee, approval number 007/EA/
KEPK.RSBM.DISKES/2020, while the use of COVID-19 
IgG and/or IgM positive samples has been approved by 
Raden Mattaher Hospital Research Ethics Committee, 
approval number S.32/SPE/VII/2020.
The specificity evaluation of COVID-19 IgG / IgM 
RDTs against confirmed dengue samples was per-
formed in a laboratory that is internationally certified 
for Good Clinical Laboratory Practice (GCLP) at the 
Eijkman Institute, Jakarta, Indonesia. The laboratory 
testing on RT-PCR-confirmed COVID-19 samples was 
performed at Bali Mandara and Sanjiwani hospitals, 
Bali, Indonesia while the laboratory testing on healthy/
asymptomatic samples positive for COVID-19 IgG 
and/or IgM was performed at Siloam Hospital, Jambi, 
Table 1 Characteristics of samples used in the study
*Incomplete data for 15 samples






samples (N = 49)
Fever day onset, mean (SD) 5 (1.5) N/A N/A
Age, median (IQR) 14 (8–22) 34 (25–46) 43 (34–52)
Age N (%)
Children ≤ 18 years 35 (58) 2 (2.1) 0 (0.0)
Adults > 18 years 25 (42) 78 (82.1) 49 (100)
Gender
Male 28 (47) 49 (51.6) 34 (69.4)
Female 32 (53) 31 (32.6) 15 (30.6)
Serotype
DENV-1 15 (25) N/A N/A
DENV-2 15 (25) N/A N/A
DENV-3 20 (33) N/A N/A
DENV-4 10 (17) N/A N/A
Immunologic status
Primary dengue infection 10 (17) N/A N/A
Secondary dengue infection 50 (83) N/A N/A
Presence of anti-dengue antibodies
IgG ( +), IgM ( +) 21 (35) N/A N/A
IgG ( +), IgM (−) 16 (27) N/A N/A
IgG (−), IgM ( +) 14 (23) N/A N/A
IgG (−), IgM (−) 9 (15) N/A N/A
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Indonesia, both with appropriate biosafety protocols. 
Dengue virus (DENV) RNA in the sera were extracted 
using QIAamp Viral RNA mini kit (Qiagen, Germany) 
according to the manufacturer’s instructions. Detection 
and serotyping of DENV was performed using CDC 
DENV-1-4 real-time RT-PCR assay according to given 
instructions (Package Insert, KK0128 available at www.
cdc.gov/dengu e). Molecular detection of SARS-CoV-2 
was performed using A*Star Fortitude COVID-19 Real-
Time RT-PCR Test and Liferiver Novel Coronavirus 
(2019-nCoV) Real Time Multiplex RT-PCR (BioVen-
dor, Czech Republic). Immunologic status for dengue 
was determined using NovaLisa Dengue Virus IgG 
ELISA (NovaTec Immundiagnostica, Germany), per-
formed according to manufacturer’s instruction. The 
confirmed-dengue samples were collected from various 
regions across Indonesia between October 2018 and 
March 2019, before the initial outbreak of COVID-19. 
The confirmed-COVID-19 patients were recruited from 
Bali, Indonesia in May 2020. The healthy/asymptomatic 
individuals that were positive for COVID-19 IgG and/
or IgM were recruited from Jambi, Indonesia from May 
to July 2020.
The COVID-19 IgG and IgM RDTs that we evaluated 
were Cellex Inc. (USA), Dynamiker Biotechnology (Tian-
jin, China), Genbody Inc. (Korea), Standard Diagnostics 
(Korea), and VivaDiag (Vivacheck Biotech Hangzhou,, 
China). Each dengue-confirmed sample was tested using 
different brands of IgG/IgM COVID-19 RDT simulta-
neously, under uniform conditions, according to their 
respective manufacturers’ instructions. Positive COVID-
19 RDT results were confirmed using SARS-CoV-2 Spike 
S1-RBD IgG & IgM ELISA Detection Kit (Genscript, 
USA). The dengue RDT kit used on confirmed COVID-
19 samples and healthy/asymptomatic samples was 
Standard Q Dengue Duo (SD Biosensor, Korea, for the 
detection of dengue NS1 antigen and IgG and IgM anti-
bodies), while the COVID-19 kit used on the healthy/
asymptomatic samples are VivaDiag COVID-19 IgG/
IgM.
For COVID-19 RDT specificity evaluation, which is the 
proportion of non-COVID-19 samples who are correctly 
identified as negative for SARS-CoV-2 antibodies using 
the COVID-19 RDTs, sample size was calculated based 
on the three-step method [10] with an expected speci-
ficity of 96%, a precision of 7.5%, and 90% power, which 
yields 60 presumed COVID-19-negative samples. Overall 
specificity of each RDT brand, as well as when stratified 
into variable groups, were compared using Z-tests for 
proportions. Specificity, confidence intervals, and other 
statistical analyses were performed using R Studio soft-
ware, with p-value of less than 0.05 denoting statistical 
significance.
Results
We observed a high specificity across all COVID-19 RDT 
brands against dengue-confirmed samples, ranging from 
98.3 to 100% and no statistically significant difference in 
overall performance between brands, or when grouped 
by age, gender, day of fever onset, DENV serotype, and 
immunologic status (Table 2). One sample which tested 
positive for COVID-19 IgG using SD Biosensor Den-
gue RDT was a 17-year-old male, with fever day onset 
of 2 days, infected with DENV-4, and tested positive for 
anti-dengue IgG and IgM. One other sample which tested 
positive for COVID-19 IgM using Cellex and SD Biosen-
sor Dengue RDT was a 23-year-old male, with fever day 
onset of 8 days, infected with DENV-2, and tested posi-
tive for anti-dengue IgM and negative for anti-dengue 
IgG. However, neither of these samples tested positive for 
IgG or IgM using SARS-CoV-2 ELISA, suggesting false-
positive results on the RDT.
Among 95 RT-PCR confirmed COVID-19 patient sam-
ples, one patient tested positive for dengue IgM only, 
another tested positive for dengue IgG only. One patient 
tested positive for both dengue IgG and IgM as well as 
NS1, demonstrating the possibility of coinfection of den-
gue and COVID-19 or recent dengue infection (Table 3).
In healthy/asymptomatic samples, out of 33 samples 
that tested positive for COVID-19 IgG, 2 samples (6.1%) 
also tested positive for dengue IgG, while out of 19 sam-
ples that tested positive for COVID-19 IgM, 4 samples 
(21.1%) also tested positive for dengue IgG (Table 3).
Discussion
While there is a possibility of cross-reactivity between 
SARS-CoV-2 and DENV antibodies, there is good 
overall performance of COVID-19 RDTs. Another 
study shows no cross reactivity with other respiratory 
Table 2 Specificity comparison of five brands of COVID-19 RDTs 
against dengue-confirmed samples
Specificity (%, 95% CI)
IgG IgM
Cellex 100% (95% CI 
92.5–100)
98.3% (95% CI 89.9–99.9)
Dynamiker 100% (95% CI 
92.5–100)
100% (95% CI 92.5–100)
Genbody 100% (95% CI 
92.5–100)
100% (95% CI 92.5–100)
Standard diagnostics 98.3% (95% CI 
89.9–99.9)
98.3% (95% CI 89.9–99.9)
VivaChek 100% (95% CI 
92.5–100)
100% (95% CI 92.5–100)
p-value 0.404 0.555
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pathogens that may have similar clinical symptoms as 
COVID-19 [11]. Apparent cross-reactivity between 
DENV and SARS-CoV-2 antibodies in dengue RDT 
has been reported in two confirmed COVID-19 cases 
in Singapore [7]. However, more in-depth studies are 
needed to fully understand the interaction between 
these antibodies.
We found that in terms of specificity, different 
COVID-19 RDT brands perform similarly to each 
other, comparable to findings in other studies [12]. 
However, these studies also show that different RDT 
brands have varying levels of sensitivity [12]. A meta-
analysis of COVID-19 serological tests measured the 
pooled sensitivity of lateral flow immunoassays to be 
66.0% (95% CI 49.3–79.3%) [13]. Taking that sensitiv-
ity as a reference, the rapid tests in our study have a 
negative predictive value (NPV) of 92.2% even at pop-
ulations with 20% prevalence. The ability to rapidly 
confirm the absence of COVID-19 would be useful in 
allocating resources for isolation and protecting the 
patient from nosocomial COVID-19 infections espe-
cially in settings where the patient may have other viral 
infections that require hospitalization, such as dengue. 
Additionally, the ability to accurately rule out dengue 
in acutely febrile patients would quickly lead to the 
investigation and management of other differential 
diagnoses such COVID-19 that would require timely 
isolation and contact tracing.
One of the limitations in this study is we did not assess 
the sensitivity of COVID-19 RDT data. Another limita-
tion is that we could not conduct repeat testing of den-
gue antibodies in the COVID-19 confirmed samples and 
therefore cannot rule out the possibility of recent but not 
concurrent dengue infection. Additionally, conditions on 
site unfortunately did not make it possible to follow-up 
with RT-PCR for DENV. However, the positive anti den-
gue virus NS1 antigen result has been widely accepted 
as “confirmed dengue” (WHO SEARO Dengue Guide-
lines 2011). We also could not assess for cross-reactivity 
with other coronavirus infections, auto-immune disease, 
or immunodeficiency. Nevertheless, our data provide 
important information on the prospective use of these 
RDTs in regions that are endemic for dengue during the 
COVID-19 pandemic.
Conclusion
Our study observed that despite the high specificity of 
the COVID-19 RDT, cross-reactions and false-positive 
results between dengue and COVID-19 are very likely. 
Dengue and COVID-19 co-infection can also occur. To 
the authors’ knowledge, this is the first study reporting 
on the performance of COVID-19 rapid tests on dengue-
confirmed samples. Our study adds important informa-
tion on the possible cross-reaction between dengue and 
COVID-19 in Indonesia, though more studies are needed 
to further evaluate these interactions. Health practition-
ers should be careful when using antibody RDT for the 
diagnosis of dengue during the COVID-19 pandemic to 
avoid misdiagnosis.
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95 1 (1.1) 2 (2.1) 2 (2.1)
COVID-19 IgG RDT 
positive
33 0 (0.0) 2 (6.1) 0 (0.0)
COVID-19 IgM RDT 
positive
19 0 (0.0) 4 (21.1) 0 (0.0)
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